The development of a new therapeutic moleculefor Japanese cedar pollinosis by proteomics analysis in the serum of patients treated with sublingual immunotherapy

通过舌下免疫治疗患者血清的蛋白质组学分析开发日本柳杉花粉病的新治疗分子

• 批准号: 20390441
• 负责人: FUJIEDA Shigeharu
• 金额: $ 12.65万
• 依托单位: University of Fukui
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20390441/
• 关键词: 鼻科学; アレルギー学; スギ花粉症; 舌下免疫療法; 網羅的蛋白解析; アポ蛋白A-4; DAF; Filaggrin; ORMDL3; Intelectin-1; スフィンゴシン1リン酸; 遺伝子多型; IL-17; アポ蛋白A-IV; IL-33; CpG-DNA; 乳酸菌; PD-L1; C4A; トランスサイレチン; Hepatocyte nuclear factor 4α

Seasonal allergic rhinitis caused by Japanese cedar (SAR-JC) is the most common allergic disease in Japan. The results of our recent study showed that about 30% of Japanese individuals develop allergic symptoms during JC pollination season. Allergen-specific immunotherapy (SIT) is the only available treatment that can provide long-term remission after discontinuation of treatment. Sublingual immunotherapy (SLIT), oral administration of the allergen, was introduced as a safety method. We found that apolipoprotein A-IV (apoA-IV) were significantly increased in SLIT-treated patients. The serum levels of apoA-IV correlated with the clinical effect. The amount of histamine released from the basophils in vitro was greatly reduced after the addition of recombinant apoA-IV in the medium. Our genetic studies found the association of polymorphisms of IL-33, DAF and Filaggrin with SAR-JC. They are possible therapeutic targets for SAR-JC.

日本雪松引起的季节性过敏性鼻炎(SAR-JC)是日本最常见的过敏性疾病。我们最近的研究结果显示，大约30%的日本人在JC授粉季节出现过敏症状。过敏原特异性免疫疗法(SIT)是唯一可以在停止治疗后提供长期缓解的治疗方法。舌下免疫疗法(SIT)，即口服过敏原，是一种安全的方法。我们发现缝隙治疗的患者载脂蛋白A-IV(apoA-IV)显著升高。血清载脂蛋白A-IV水平与临床疗效相关。加入重组apoA-IV后，嗜碱性粒细胞体外释放组胺的量大大减少。我们的遗传学研究发现IL-33、DAF和Filaggrin基因多态性与SAR-JC相关。它们可能是SAR-JC的治疗靶点。

项目成果

スギ花粉症における網羅的遺伝子・蛋白解析

雪松花粉病的基因和蛋白质综合分析

• 发表时间: 2008
• 作者: Higuchi K;Kimura O;Iwai N;藤枝重治
• 通讯作者: 藤枝重治

Poly(I:C) induces BLyS-expression of airway fibroblasts through phosphatidylinositol 3-kinase.

Poly(I:C) 通过磷脂酰肌醇 3-激酶诱导气道成纤维细胞表达 BLyS。

• 发表时间: 2010
• 期刊: Cytokine
• 影响因子: 3.8
• 作者: Yamada T;(他7人)
• 通讯作者: (他7人)

Apolipoprotein A-IV is a candidate target molecule for the treatment of seasonal allergic rhinitis

• DOI: 10.1016/j.jaci.2010.06.031
• 发表时间: 2010-12-01
• 期刊: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
• 影响因子: 14.2
• 作者: Makino, Yuka;Noguchi, Emiko;Fujieda, Shigeharu
• 通讯作者: Fujieda, Shigeharu

Efficacy of oral olopatadine hydrochloridefor the treatment of seasonal allergic rhinitis: A randomized, double-blind,placebo-controlled study.

口服盐酸奥洛他定治疗季节性过敏性鼻炎的疗效：一项随机、双盲、安慰剂对照研究。

• 发表时间: 2010
• 期刊: Allergy Asthma Proc.
• 作者: Yamamoto H;Yamada T;(他8人)
• 通讯作者: (他8人)

Platelet derived endothelial cell growth factor/thymidine phosphorylase enhanced human IgE production

血小板源性内皮细胞生长因子/胸苷磷酸化酶增强人 IgE 产生

• 发表时间: 2011
• 期刊: Allergology International 60-61
• 作者: Hideyuki Yamamoto;Takechiyo Yamada;Tetsuji Takabayashi;Hiroshi Sunaga;Myungmi Oh;Norihiko Narita;Akihiro Kojima;Shigeharu Fujieda
• 通讯作者: Shigeharu Fujieda